



The following short copy may be used in an outreach newsletter.

SHORT

(HEAD OPTIONS)

Do You Have a Patient with Dyskinesia Due to Cerebral Palsy?

Research Opportunity for Patients with Dyskinesia Due to Cerebral Palsy

(COPY)

██████████ is looking for patients aged 6 to 70 years old with dyskinesia due to cerebral palsy (DCP) for the ██████████ Study. The purpose of the study is to determine if a study drug, called ██████████, is safe to use and if it helps to improve dyskinesia due to cerebral palsy (CP). To learn more or refer a patient, contact the participating research site listed here.

[BLANK BOX FOR SITE CONTACT INFORMATION]

(LOGO)

██████████ Study

The following medium copy may be used in an outreach Newsletter.

MEDIUM

(HEAD OPTIONS)

Do You Have a Patient with Dyskinesia Due to Cerebral Palsy?

Research Opportunity for Patients with Dyskinesia Due to Cerebral Palsy

(COPY)

The ██████████ Study is a clinical research study for individuals with dyskinesia due to cerebral palsy (DCP). The purpose of the ██████████ Study is to determine if a study drug, called ██████████, is safe to use and if it helps improve dyskinesia due to cerebral palsy (CP). ██████████, a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, is thought to work by reducing the amount of dopamine released in a region of the brain that controls movement and motor function.

Eligible participants must:

- Be 6 to 70 years of age
- Have a medically confirmed diagnosis of DCP with choreiform movements
- Not have a predominant movement disorder other than dystonia and/or choreoathetosis as the main cause of impairment and/or distress

Other criteria apply. To learn more or refer a patient, contact the participating research site listed here.

[BLANK BOX FOR SITE CONTACT INFORMATION]

(LOGO)

██████████ Study

The following long copy may be used in an outreach newsletter.

LONG

(HEAD OPTIONS)

Do You Have a Patient with Dyskinesia Due to Cerebral Palsy?

Research Opportunity for Patients with Dyskinesia Due to Cerebral Palsy

(COPY)

The [REDACTED] Study is a clinical research study for individuals with dyskinesia due to cerebral palsy (DCP). The purpose of the [REDACTED] Study is to determine if a study drug, called [REDACTED], is safe to use and if it helps improve dyskinesia due to cerebral palsy (CP). [REDACTED], a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, taken once daily, is thought to work by reducing the amount of dopamine released in a region of the brain that controls movement and motor function.

Interested individuals will be screened for eligibility for up to 6 weeks, and eligible participants will be randomized 1:1 to receive [REDACTED] or placebo in the first treatment period, which lasts 14 weeks. In the second treatment period, which lasts 32 weeks, all participants will receive [REDACTED]. Doses will be based on age and weight and adjusted during the study based on tolerability. The total duration of participation is approximately 56 weeks.

Eligible participants must:

- Be 6 to 70 years of age (inclusive)
- Have a medically confirmed diagnosis of DCP with choreiform movements
- Not have a predominant movement disorder other than dystonia and/or choreoathetosis as the main cause of impairment and/or distress

Other criteria may apply. To learn more or refer a patient, contact the participating research site listed here.

[BLANK BOX FOR SITE CONTACT INFORMATION]

(LOGO)

[REDACTED] Study

(FOOTER)

[REDACTED]